Neoadjuvant lazertinib

Phase 2Small molecule

KKonkuk University Medical Center

Neoadjuvant lazertinib is one of 48 small molecule programs targeting Lung Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung AdenocarcinomaActive, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Lung Adenocarcinoma

#DrugCompanyPhaseTrials

Iressa

AstraZeneca

Phase 3

7 2

Keytruda

Merck & Co.

Phase 3

4 3

Lorbrena

Pfizer

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

7 5

Navelbine

PPierre Fabre Medicament

Phase 3

2 6

Tagrisso

AstraZeneca

Phase 2

2 7

Sutent

Pfizer

Phase 2

2 8

Neulasta

Amgen

Phase 2

1 9

Nexavar

Bayer

Phase 2

1 10

Eylea

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Lung Adenocarcinoma

NCT05469022

Clinical

Trials by Indication[1]

Lung Adenocarcinoma1 trial

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Recruiting·KKonkuk University Medical Center·Phase 2·NCT05469022·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neoadjuvant lazertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant lazertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant lazertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Konkuk University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKonkuk University Medical Center

Neoadjuvant lazertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Lung Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News